At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
NBT-NM108drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Understanding the Role of Gut Microbiota in Hyperphagia in Prader-Willi Syndrome
In Brief
A Phase 2 clinical trial evaluating NBT-NM108 for Prader-Willi Syndrome and Obesity. Completed, enrolled 12 participants across 1 site.
Detailed Summary
This study aims to use a high-fiber supplementation, an intervention known to create shifts in the gut microbiota towards a healthier structure, to explore the relationship between gut microbiota, appetite control and feeding behavior in PWS patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrader-Willi Syndrome, Obesity
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedSep 2022
Enrollment StartJan 2023
Primary CompletionMay 2023
Study CompletionMay 2023
TodayJul 2026
First PostedSep 15, 2022
Enrollment StartJan 6, 2023
Primary CompletionMay 29, 2023
Study CompletionMay 30, 2023
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 3.8 years ago
Interventions
NBT-NM108drug
All patients will consume NBT-NM108 in the form of 2 muffins daily.